Phanes Therapeutics Expands Merck Clinical Trial Collaboration for Biliary Tract Cancer
Phanes Therapeutics expanded its clinical trial collaboration with Merck to evaluate spevatamig in combination with KEYTRUDA for biliary tract cancer.
Phanes Therapeutics
Private
Phanes Therapeutics is a clinical-stage biotechnology company focused on innovative drug discovery and development in oncology. Recently expanded its clinical trial collaboration with Merck to evaluate spevatamig in combination with KEYTRUDA for biliary tract cancer.
Company Info
Upcoming Milestones & Key Dates
Q4 2026
Clinical
Phase 2 interim readout
Clinical Development Pipeline
Spevatamig
Target: PD-L1/CD55Undisclosed
Target: TBDUndisclosed
Target: TBDRecent News
Leadership Team
To be confirmed
Chief Executive Officer
To be confirmed
Chief Medical Officer
To be confirmed
Chief Scientific Officer
Careers & Job Openings